User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.

Primary tabs

Vornicu, Ovidiu Ionut [UCL] Larock, Anne-Sophie [UCL] Dincq, Anne-Sophie [UCL] Douxfils, Jonathan Dogné, Jean-Michel Mullier, François [UCL] Lessire, Sarah [UCL]

Idarucizumab is a specific antagonist for dabigatran etexilate (DE). The recent market authorization of idarucizumab in Europe and the USA may reassure prescribers of DE, as it can increase the safety of the emergency management of patients taking this anticoagulant. However, idarucizumab use should be limited to specific indications to avoid unnecessary risks to patients and costs to healthcare systems. Areas covered: The authors provide an overview of idarucizumab development and its pharmacokinetic and pharmacodynamic properties. The results of the clinical phase III trial RE-VERSE AD and a review of recent case reports of idarucizumab use in emergency contexts are also discussed. Expert opinion: Although idarucizumab has shown clear efficacy in reversing dabigatran-induced coagulopathy, its overall effects on patient outcome have not been proven. Information regarding the clinical context in which patients on DE are admitted for emergency treatment, and accurate laboratory tests of dabigatran plasma level during reversal may inform selection and help with the follow-up of patients who may benefit from idarucizumab. Idarucizumab should be integrated into protocol for the emergency management of patients on DE. Furthermore, the benefit of idarucizumab in specific indications such as acute ischemic stroke should be investigated.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2017
Language Anglais
Journal information "Expert Opinion on Biological Therapy" - Vol. 17, no. 10, p. 1275-1296 (2017)
Peer reviewed yes
Publisher Taylor & Francis ((United Kingdom) Abingdon)
issn 1471-2598
e-issn 1744-7682
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - SSS/LDRI - Louvain Drug Research Institute
UCL - SSS/IREC/MEDA - Pôle de médecine aiguë
UCL - (MGD) Service d'anesthésiologie
UCL - (MGD) Département de pharmacie
UCL - (MGD) Laboratoire de biologie clinique
Keywords Anticoagulants ; Bleeding ; Blood coagulation test ; Dabigatran ; Emergency care ; Idarucizumab ; Invasive procedures ; Perioperative period
Links
  1. Sholzberg Michelle, Pavenski Katerina, Shehata Nadine, Cserti-Gazdewich Christine, Lin Yulia, Bleeding complications from the direct oral anticoagulants, 10.1186/s12878-015-0039-z
  2. Southworth Mary Ross, Reichman Marsha E., Unger Ellis F., Dabigatran and Postmarketing Reports of Bleeding, 10.1056/nejmp1302834
  3. Harenberg J., Marx S., Dahl O. E., Marder V. J., Schulze A., Wehling M., Weiss C., Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery : , 10.1160/th12-07-0482
  4. Huisman Menno V., Rothman Kenneth J., Paquette Miney, Teutsch Christine, Diener Hans Christoph, Dubner Sergio J., Halperin Jonathan L., Ma Changsheng, Zint Kristina, Elsaesser Amelie, Bartels Dorothee B., Lip Gregory Y.H., Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II, 10.1016/j.amjmed.2015.07.013
  5. Levy Jerrold H., Spyropoulos Alex C., Samama Charles M., Douketis James, Direct Oral Anticoagulants, 10.1016/j.jcin.2014.06.014
  6. Connolly S. J., Wallentin L., Ezekowitz M. D., Eikelboom J., Oldgren J., Reilly P. A., Brueckmann M., Pogue J., Alings M., Amerena J. V., Avezum A., Baumgartner I., Budaj A. J., Chen J.-H., Dans A. L., Darius H., Di Pasquale G., Ferreira J., Flaker G. C., Flather M. D., Franzosi M. G., Golitsyn S. P., Halon D. A., Heidbuchel H., Hohnloser S. H., Huber K., Jansky P., Kamensky G., Keltai M., Kim S. S., Lau C.-P., Le Heuzey J.-Y., Lewis B. S., Liu L., Nanas J., Omar R., Pais P., Pedersen K. E., Piegas L. S., Raev D., Smith P. J., Talajic M., Tan R. S., Tanomsup S., Toivonen L., Vinereanu D., Xavier D., Zhu J., Wang S. Q., Duffy C. O., Themeles E., Yusuf S., The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study, 10.1161/circulationaha.112.001139
  7. Connolly Stuart J., Ezekowitz Michael D., Yusuf Salim, Eikelboom John, Oldgren Jonas, Parekh Amit, Pogue Janice, Reilly Paul A., Themeles Ellison, Varrone Jeanne, Wang Susan, Alings Marco, Xavier Denis, Zhu Jun, Diaz Rafael, Lewis Basil S., Darius Harald, Diener Hans-Christoph, Joyner Campbell D., Wallentin Lars, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa0905561
  8. Ezekowitz Michael D., Eikelboom John, Oldgren Jonas, Reilly Paul A., Brueckmann Martina, Kent Anthony P., Pogue Janice, Spahr Judith, Clemens Andreas, Noack Herbert, Diener Hans-Christoph, Wallentin Lars, Yusuf Salim, Connolly Stuart J., Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation, 10.1093/europace/euv312
  9. Larsen TB, BMJ (Clinical Research Ed), 16, i3189 (2016)
  10. Nielsen Peter Brønnum, Skjøth Flemming, Søgaard Mette, Kjældgaard Jette Nordstrøm, Lip Gregory Y H, Larsen Torben Bjerregaard, Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, 10.1136/bmj.j510
  11. Graham D. J., Reichman M. E., Wernecke M., Zhang R., Southworth M. R., Levenson M., Sheu T.-C., Mott K., Goulding M. R., Houstoun M., MaCurdy T. E., Worrall C., Kelman J. A., Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation, 10.1161/circulationaha.114.012061
  12. Graham David J., Reichman Marsha E., Wernecke Michael, Hsueh Ya-Hui, Izem Rima, Southworth Mary Ross, Wei Yuqin, Liao Jiemin, Goulding Margie R., Mott Katrina, Chillarige Yoganand, MaCurdy Thomas E., Worrall Chris, Kelman Jeffrey A., Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation, 10.1001/jamainternmed.2016.5954
  13. Hijazi Z., Hohnloser S. H., Oldgren J., Andersson U., Connolly S. J., Eikelboom J. W., Ezekowitz M. D., Reilly P. A., Siegbahn A., Yusuf S., Wallentin L., Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis, 10.1161/circulationaha.113.003628
  14. Beyer-Westendorf J., Ebertz F., Förster K., Gelbricht V., Michalski F., Köhler C., Werth S., Endig H., Pannach S., Tittl L., Sahin K., Daschkow K., Weiss N., Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation : Results from the Dresden NOAC Registry, 10.1160/th14-11-0954
  15. Hernandez Inmaculada, Baik Seo Hyon, Piñera Antonio, Zhang Yuting, Risk of Bleeding With Dabigatran in Atrial Fibrillation, 10.1001/jamainternmed.2014.5398
  16. Russo V, Eur Rev Med Pharmacol Sci, 19, 3961 (2015)
  17. Healey J. S., Eikelboom J., Douketis J., Wallentin L., Oldgren J., Yang S., Themeles E., Heidbuchel H., Avezum A., Reilly P., Connolly S. J., Yusuf S., Ezekowitz M., , Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, 10.1161/circulationaha.111.090464
  18. Beyer-Westendorf J., Gelbricht V., Forster K., Ebertz F., Kohler C., Werth S., Kuhlisch E., Stange T., Thieme C., Daschkow K., Weiss N., Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry, 10.1093/eurheartj/eht557
  19. Spyropoulos A. C., Al-Badri A., Sherwood M. W., Douketis J. D., Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery, 10.1111/jth.13305
  20. Schiele F., van Ryn J., Canada K., Newsome C., Sepulveda E., Park J., Nar H., Litzenburger T., A specific antidote for dabigatran: functional and structural characterization, 10.1182/blood-2012-11-468207
  21. Glund Stephan, Stangier Joachim, Schmohl Michael, Gansser Dietmar, Norris Stephen, van Ryn Joanne, Lang Benjamin, Ramael Steven, Moschetti Viktoria, Gruenenfelder Fredrik, Reilly Paul, Kreuzer Jörg, Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial, 10.1016/s0140-6736(15)60732-2
  22. Glund S., Moschetti V., Norris S., Stangier J., Schmohl M., van Ryn J., Lang B., Ramael S., Reilly P., A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran : , 10.1160/th14-12-1080
  23. Meibohm Bernd, Zhou Honghui, Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics, 10.1177/0091270011413894
  24. Christensen E. I., Birn H., Storm T., Weyer K., Nielsen R., Endocytic Receptors in the Renal Proximal Tubule, 10.1152/physiol.00022.2012
  25. Glund Stephan, Stangier Joachim, van Ryn Joanne, Schmohl Michael, Moschetti Viktoria, Haazen Wouter, De Smet Marina, Gansser Dietmar, Norris Stephen, Lang Benjamin, Reilly Paul, Kreuzer Jörg, Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study, 10.1007/s40262-016-0417-0
  26. Grottke Oliver, Honickel Markus, van Ryn Joanne, ten Cate Hugo, Rossaint Rolf, Spronk Henri M., Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation, 10.1016/j.jacc.2015.07.051
  27. Honickel MVRJ, J Thromb Haemostasis, 13, 119 (2015)
  28. Honickel M., Treutler S., van Ryn J., Tillmann S., Rossaint R., Grottke O., Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab : , 10.1160/th14-08-0712
  29. Honickel Markus, Braunschweig Till, van Ryn Joanne, ten Cate Hugo, Spronk Henri M. H., Rossaint Rolf, Grottke Oliver, Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model : , 10.1097/aln.0000000000000863
  30. Grottke O., Zentai C., van Ryn J., ten Cate H., Rossaint R., Spronk H., Binding of dabigatran to its specific antidote, idarucizumab, is not influenced by infusion solutions used during resuscitation in a porcine hemorrhagic shock model : 6AP3-6, 10.1097/00003643-201406001-00265
  31. Na Shin-Young, Mracsko Eva, van Ryn Joanne, Veltkamp Roland, Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran : Dabigatran Reversal in ICH, 10.1002/ana.24421
  32. Arellano-Rodrigo E, Blood, 124, 2878 (2014)
  33. Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
  34. van Ryn J, Blood, 128, 2627 (2016)
  35. Norris Stephen, Ramael Steven, Ikushima Ippei, Haazen Wouter, Harada Akiko, Moschetti Viktoria, Imazu Susumu, Reilly Paul A., Lang Benjamin, Stangier Joachim, Glund Stephan, Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies : Idarucizumab immunogenicity during Phase I, 10.1111/bcp.13269
  36. Schmohl M., Glund S., Harada A., Imazu S., De Smet M., Moschetti V., Ramael S., Ikushima I., Grünenfelder F., Reilly P., Stangier J., Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers : , 10.1160/th16-05-0385
  37. Glund Stephan, Reilly Paul, van Ryn Joanne, Stangier Joachim, Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”, 10.1007/s40262-016-0493-1
  38. Glund Stephan, Stangier Joachim, van Ryn Joanne, Schmohl Michael, Moschetti Viktoria, Haazen Wouter, De Smet Marina, Gansser Dietmar, Norris Stephen, Lang Benjamin, Reilly Paul, Kreuzer Jörg, Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers, 10.1016/j.jacc.2016.01.043
  39. van Ryn J, Circulation, 130, A18403 (2014)
  40. Pollack C. V., Reilly P. A., Bernstein R., Dubiel R., Eikelboom J., Glund S., Huisman M. V., Hylek E., Kam C.-W., Kamphuisen P. W., Kreuzer J., Levy J. H., Sellke F., Stangier J., Steiner T., Wang B., Weitz J. I., Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran : , 10.1160/th15-03-0192
  41. Schulman Sam, Ritchie B., Nahirniak S., Gross P.L., Carrier M., Majeed A., Hwang H.-G., Zondag M., Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study, 10.1016/j.thromres.2017.02.010
  42. Levy J. H., Ageno W., Chan N. C., Crowther M., Verhamme P., Weitz J. I., , When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH, 10.1111/jth.13227
  43. Kirchhof Paulus, Benussi Stefano, Kotecha Dipak, Ahlsson Anders, Atar Dan, Casadei Barbara, Castella Manuel, Diener Hans-Christoph, Heidbuchel Hein, Hendriks Jeroen, Hindricks Gerhard, Manolis Antonis S., Oldgren Jonas, Popescu Bogdan Alexandru, Schotten Ulrich, Van Putte Bart, Vardas Panagiotis, Agewall Stefan, Camm John, Baron Esquivias Gonzalo, Budts Werner, Carerj Scipione, Casselman Filip, Coca Antonio, De Caterina Raffaele, Deftereos Spiridon, Dobrev Dobromir, Ferro José M., Filippatos Gerasimos, Fitzsimons Donna, Gorenek Bulent, Guenoun Maxine, Hohnloser Stefan H., Kolh Philippe, Lip Gregory Y. H., Manolis Athanasios, McMurray John, Ponikowski Piotr, Rosenhek Raphael, Ruschitzka Frank, Savelieva Irina, Sharma Sanjay, Suwalski Piotr, Tamargo Juan Luis, Taylor Clare J., Van Gelder Isabelle C., Voors Adriaan A., Windecker Stephan, Zamorano Jose Luis, Zeppenfeld Katja, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, 10.1093/europace/euw295
  44. Raval Amish N., Cigarroa Joaquin E., Chung Mina K., Diaz-Sandoval Larry J., Diercks Deborah, Piccini Jonathan P., Jung Hee Soo, Washam Jeffrey B., Welch Babu G., Zazulia Allyson R., Collins Sean P., Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association, 10.1161/cir.0000000000000477
  45. Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
  46. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.-M., Impact of dabigatran on a large panel of routine or specific coagulation assays : Laboratory recommendations for monitoring of dabigatran etexilate, 10.1160/th11-11-0804
  47. Cuker Adam, Siegal Deborah M., Crowther Mark A., Garcia David A., Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants, 10.1016/j.jacc.2014.05.065
  48. Lessire Sarah, Douxfils Jonathan, Baudar Justine, Bailly Nicolas, Dincq Anne-Sophie, Gourdin Maximilien, Dogné Jean-Michel, Chatelain Bernard, Mullier François, Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study, 10.1016/j.thromres.2015.07.018
  49. Carvalho Manuela, Rodrigues Anabela, Gomes Manuela, Carrilho Alexandre, Nunes António Robalo, Orfão Rosário, Alves Ângela, Aguiar José, Campos Manuel, Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings : Recommendations From the Share Network Group, 10.1177/1076029614559773
  50. Douxfils J., Lessire S., Dincq A.-S., Hjemdahl P., Rönquist-Nii Y., Pohanka A., Gourdin M., Chatelain B., Dogné J.-M., Mullier F., Estimation of dabigatran plasma concentrations in the perioperative setting : An ex vivo study using dedicated coagulation assays, 10.1160/th14-09-0808
  51. Lessire Sarah, Douxfils Jonathan, Dincq Anne-Sophie, Mullier François, Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests : , 10.1097/aap.0000000000000448
  52. Mani H., Rohde G., Stratmann G., Hesse C., Herth N., Schwers S., Perzborn E., Lindhoff-Last E., Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin : , 10.1160/th11-12-0832
  53. Königsbrügge Oliver, Quehenberger Peter, Belik Sabine, Weigel Günter, Seger Christoph, Griesmacher Andrea, Pabinger Ingrid, Ay Cihan, Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban, 10.1007/s00277-015-2407-y
  54. Lessire Sarah, Douxfils Jonathan, Pochet Lionel, Dincq Anne-Sophie, Larock Anne-Sophie, Gourdin Maximilien, Dogné Jean-Michel, Chatelain Bernard, Mullier François, Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging, 10.1177/1076029616675968
  55. Tripodi A., The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment, 10.1111/jth.13750
  56. Tripodi A., The laboratory and the direct oral anticoagulants, 10.1182/blood-2012-12-453076
  57. Weitz Jeffrey I., Eikelboom John W., Urgent Need to Measure Effects of Direct Oral Anticoagulants: Table., 10.1161/circulationaha.116.022307
  58. Jacquemin M., Toelen J., Schoeters J., van Horenbeeck I., Vanlinthout I., Debasse M., Peetermans M., Vanassche T., Peerlinck K., van Ryn J., Verhamme P., The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders, 10.1111/jth.13138
  59. Mazur P, Pol Arch Med Wewn, 126, 579 (2016)
  60. Hofer Stefan, Philipsenburg Christoph, Weigand Markus A., Brenner Thorsten, Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab : A Case Report, 10.1213/xaa.0000000000000395
  61. Vosko Milan R., Bocksrucker Christof, Drwiła Rafał, Dulíček Petr, Hauer Tomas, Mutzenbach Johannes, Schlimp Christoph J., Špinler David, Wolf Thomas, Zugwitz Daša, Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases, 10.1007/s11239-017-1476-2
  62. Sauter TC, Case Rep Emerg Med, 2016, 1393057 (2016)
  63. Thorborg C., Horn E.-P., Mofid H., Langer F., Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus, 10.1093/bja/aew244
  64. Marino Kaylee K., Santiago Raul A., Dew Richard B., Berliner Nancy, Connors Jean M., Connell Nathan T., Tucker John Kevin, Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis, 10.1002/phar.1830
  65. Rottenstreich Amihai, Jahshan Nivin, Avraham Limor, Kalish Yosef, Idarucizumab for dabigatran reversal – Does one dose fit all?, 10.1016/j.thromres.2016.09.006
  66. Simon A., Domanovits H., Ay C., Sengoelge G., Levy J. H., Spiel A. O., The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran, 10.1111/jth.13706
  67. Quintard H., Viard D., Drici M.-D., Ruetsch C., Samama C. M., Ichai C., Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding : , 10.1160/th16-06-0445
  68. Stecher Adela, Vene Nina, Mavri Alenka, Mijovski Mojca Božič, Krevel Barbara, Gradišek Primož, Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure : , 10.1097/eja.0000000000000617
  69. Novak JE, Am J Kidney Dis (2017)
  70. Rosenberg Lene, Gerstrøm Gustav, Nybo Mads, Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report, 10.1111/bcpt.12696
  71. Tomaszuk-Kazberuk A, Pol Arch Med Wewn, 127, 68 (2017)
  72. Held Valentin, Eisele Philipp, Eschenfelder Christoph C., Szabo Kristina, Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran, 10.1159/000452096
  73. Quintavalla R., Lombardi M., Prandoni P., Manotti C., Tadonio I., Re F., Ferrini P. M., Tassoni M. I., Rossetti P., Quaini F., Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab, 10.1007/s40520-017-0752-5
  74. Rimsans Jessica, Rhoten Megan, Sylvester Katelyn, Singh Steve K., Connors Jean M., Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report : RIMSANS et al., 10.1002/ajh.24638
  75. Braemswig Tim Bastian, Eschenfelder Christoph C, Nolte Christian H, Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab, 10.1016/j.ajem.2016.10.068
  76. Gendron Nicolas, Feral-Pierssens Anne Laure, Jurcisin Igor, de Raucourt Emmanuelle, Bouton Valerie, Fischer Anne Marie, Lorenceau-Savale Camille, Lillo-Le Louët Agnès, Smadja David M., Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding, 10.1002/ccr3.839
  77. Shapiro Susan, Bhatnagar Neha, Khan Asif, Beavis James, Keeling David, Idarucizumab for dabigatran overdose in a child, 10.1111/bjh.14371
  78. Peetermans Marijke, Pollack Charles, Reilly Paul, Liesenborghs Laurens, Jacquemin Marc, Levy Jerrold H., Weitz Jeffrey I., Verhamme Peter, Idarucizumab for dabigatran overdose, 10.1080/15563650.2016.1187737
  79. Kafke Waldemar, Kraft Peter, Department of Neurology, Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report, 10.1159/000447531
  80. Mutzenbach Johannes Sebastian, Pikija Slaven, Otto Ferdinand, Halwachs Ursula, Weymayr Friedrich, Sellner Johann, Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report, 10.1002/acn3.346
  81. Schäfer Niklas, Müller Andreas, Wüllner Ullrich, Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab—A Case Report, 10.1016/j.jstrokecerebrovasdis.2016.05.006
  82. Schulz Joachim G., Kreps Bernard, Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke, 10.1016/j.jns.2016.09.010
  83. Ng Felix C., Bice James, Rodda Anne, Lee-Archer Matthew, Crompton Douglas E., Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis, 10.1007/s00415-017-8410-6
  84. Gawehn Annemarie, Ayari Yassine, Heuschkel Christian, Kaste Matthias, Kermer Pawel, Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report, 10.1186/s13256-016-1050-0
  85. Turine G., Peeters A., Hermans C., Eeckhoudt S., Duprez T., Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer, 10.1007/s13760-017-0751-5
  86. Bissig David, Manjunath Rashmi, Traylor Brittany R., Richman David P., Ng Kwan L., Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator, 10.1016/j.jstrokecerebrovasdis.2016.12.037
  87. Tireli Derya, He Jun, Nordling Mette Maria, Wienecke Troels, Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab—A Case Report, 10.1016/j.jstrokecerebrovasdis.2017.03.039
  88. Alhashem Hussain M., Avendano Carmen, Hayes Bryan D., Winters Michael E., Persistent life-threatening hemorrhage after administration of idarucizumab, 10.1016/j.ajem.2016.06.096
  89. Berrouschot Jörg, Stoll Anett, Hogh Theresa, Eschenfelder Christoph Cyrill, Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab: Table., 10.1161/strokeaha.116.013550
  90. Grottke Oliver, Aisenberg James, Bernstein Richard, Goldstein Patrick, Huisman Menno V., Jamieson Dara G., Levy Jerrold H., Pollack Charles V., Spyropoulos Alex C., Steiner Thorsten, del Zoppo Gregory J., Eikelboom John, Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation, 10.1186/s13054-016-1275-8
  91. Dincq Anne-Sophie, Lessire Sarah, Chatelain Bernard, Gourdin Maximilien, Dogné Jean-Michel, Mullier François, Douxfils Jonathan, Impact of the Direct Oral Anticoagulants on Activated Clotting Time, 10.1053/j.jvca.2016.09.002
  92. Vanassche Thomas, Greinacher Andreas, Verhamme Peter, Reversal of dabigatran by idarucizumab: when and how?, 10.1080/17474086.2016.1184569
  93. Stevenson John W., Minns Alicia B., Smollin Craig, Albertson Timothy E., Cantrell F. Lee, Tomaszewski Christian, Clark Richard F., An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system, 10.1016/j.ajem.2014.04.031
  94. Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Diener Hans-Christoph, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, 10.1093/europace/euv309
  95. Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Diener Hans-Christoph, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary, 10.1093/eurheartj/ehw058
  96. Demaerschalk Bart M., Kleindorfer Dawn O., Adeoye Opeolu M., Demchuk Andrew M., Fugate Jennifer E., Grotta James C., Khalessi Alexander A., Levy Elad I., Palesch Yuko Y., Prabhakaran Shyam, Saposnik Gustavo, Saver Jeffrey L., Smith Eric E., Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke : A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association, 10.1161/str.0000000000000086
  97. Cappellari Manuel, Forlivesi Stefano, Squintani Giovanna Maddalena, Facchinetti Roberto, Bovi Paolo, Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update, 10.1007/s11239-017-1485-1
  98. Kepplinger Jessica, Prakapenia Alexandra, Barlinn Kristian, Siegert Gabriele, Gehrisch Siegmund, Zerna Charlotte, Beyer-Westendorf Jan, Puetz Volker, Reichmann Heinz, Siepmann Timo, Bodechtel Ulf, Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, 10.1007/s11239-015-1229-z
  99. Eikelboom John W., Quinlan Daniel J., van Ryn Joanne, Weitz Jeffrey I., Idarucizumab : The Antidote for Reversal of Dabigatran, 10.1161/circulationaha.115.019628
  100. Schulman Sam, Bleeding Complications and Management on anticoagulant therapy, 10.1055/s-0037-1602377
  101. Pollack CV, J Med Econ, 17, 1 (2017)
  102. Huang C, J Eval Clin Pract, 19, 938 (2013)
  103. Monagle Sarah, Eikelboom John W, Ng Kuan H, Bhagirath Vinai C, Clinical implications of reversal agents for direct oral anticoagulants, 10.2217/fca-2016-0070
  104. Greinacher A., Thiele T., Selleng K., Reversal of anticoagulants: an overview of current developments : , 10.1160/th14-11-0982
  105. Greinacher A., Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia, 10.1161/01.cir.0000096056.37269.14
  106. Warkentin Theodore E, Greinacher Andreas, Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes, 10.1517/14740330902778180
  107. Lessire Sarah, Dincq Anne-Sophie, Douxfils Jonathan, Devalet Bérangère, Nicolas Jean-Baptiste, Spinewine Anne, Larock Anne-Sophie, Dogné Jean-Michel, Gourdin Maximilien, Mullier François, Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”, 10.1155/2014/347031
Bibliographic reference Vornicu, Ovidiu Ionut ; Larock, Anne-Sophie ; Dincq, Anne-Sophie ; Douxfils, Jonathan ; Dogné, Jean-Michel ; et. al. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.. In: Expert Opinion on Biological Therapy, Vol. 17, no. 10, p. 1275-1296 (2017)
Permanent URL http://hdl.handle.net/2078.1/186509